Erratum: Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines (International Journal of Oncology (2013) 42 (1263-1270) DOI: 10.3892/ijo.2013.1809);Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1263-1270

  Ibrahim, Toni ^a   Liverani, Chiara ^a   Mercatali, Laura ^a   Sacanna, Emanuele ^a   Zanoni, Michele ^a   Fabbri, Francesco ^a   Zoli, Wainer ^a   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Bone metastasis; Breast cancer; M TOR; Platinum compound; Preclinical model; Zoledronic acid

Indexed keywords

CARBOPLATIN; CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; SULFORHODAMINE B; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASSAY; BONE METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

EID: 84874612222     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3613     Document Type: Erratum

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011.
2. Coleman RE and Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66, 1987.
3. Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG and Pritchard KL: Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26:5465-5476, 2008.
4. Coleman RE: Risks and benefits of bisphosphonates. Br J Cancer 98:1736-1740, 2008.
5. Coleman RE and McCloskey EV: Bisphosphonates in oncology. Bone 49:71-76, 2011.
6. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE and Perrone MH: Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase in cholesterol biosynthesis. J Lipid Res 33:1657-1663, 1992.
7. Van Beek E, Pieterman E, Cohen L, Lowick C and Papapoulos S: Farnesyl pyrophosphatase synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108-111, 1999.
8. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A and Rogers MJ: Protein geranylgeranylation is required for osteoclast formation, function and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467-1476, 2000.
9. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J and Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961-2978, 2000.
10. Benford HL, McGowan NW, Helfrich MH, Nuttall ME and Rogers MJ: Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28:465-473, 2001.
11. Jagdev SP, Coleman RE, Shipman CM, Rostami HA and Croucher PI: The bisphosphonate, ZA, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126-1134, 2001.
12. Senaratne SG, Pirianov G, Mansi JL, Arnett T and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459-1468, 2000.
13. Derenne S, Amiot M, Barille S, et al: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14:2048-2056, 1999.
14. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61:2602-2608, 2001.
15. Shipman CM, Rogers MJ, Apperley JF, Russell RG and Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98:665-672, 1997.
16. Van der Pluijm G, Vloedgraven H, van Beek EJ, van der Wee-Pals L, Lowik C and Papapoulos S: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705, 1996.
17. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD and Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890-3894, 1997.
18. Boissier S, Ferreras M, Peyruchaud O, et al: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949-2954, 2000.
19. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L and Foidart JM: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055-1061, 2002.
20. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE and Holen I: Sequence-and schedule-dependent enhancement of ZA induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364-371, 2005.
21. Neville-Webbe HL, Evans CA, Coleman RE and Holen I: Mechanisms of the synergistic interaction between the bisphosphonate ZA and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 27:92-103, 2006.
22. Vogt U, Bielawski KP, Bosse U and Schlotter CM: Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5- fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 12:1109-1114, 2004.
23. Zhao X, Xu X, Guo L, et al: Biomarker alterations with metronomic use of low-dose ZA for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Res Treat 124:733-743, 2010.
24. Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M and Bignon YJ: Molecular insights on basal-like breast cancer. Breast Cancer Res Treat 134:21-30, 2012.
25. Sirohi B, Arnedos M, Popat S, et al: Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19:1847-1852, 2008.
26. Amadori D, Bertoni L, Flamigni A, et al: Establishment and characterization of a new cell line from primary human breast carcinoma. Breast Cancer Res Treat 28:251-260, 1993.
27. Skehan P, Storeng R, Scudiero D, et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112, 1990.
28. Monks A, Scudiero D, Skehan P, et al: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766, 1991.
29. Kern DH, Morgan CR and Hildebrand-Zanki SU: In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum (II). Cancer Res 48:117-121, 1988.
30. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M and Zunino F: In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 41:385-390, 1998.
31. Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H and Bache M: Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 5:82, 2010.
32. Senaratne SG, Mansi JL and Colston KW: The bisphosphonate ZA impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 86:1479-1486, 2002.
33. Rachner TD, Singh SK, Schoppet M, et al: ZA induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287:109-116, 2010.
34. Guise TA: Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 34:19-24, 2008.
35. Fabbri F, Brigliadori G, Carloni S, et al: Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med 6:43, 2008.
36. Curigliano G and Goldhirsch A: Triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monogr, pp108-110, 2011.
37. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011.
38. Benassi MS, Chiechi A, Ponticelli F, et al: Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett 250:194-205, 2007.
39. Ozturk OH, Bozcuk H, Burgucu D, Ekinci D, Ozdogan M, Akca S and Yildiz M: Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int 31:1069-1071, 2007.
40. Fujise K, Zhang D, Liu J and Yeh ET: Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J Biol Chem 275:39458-39465, 2000.
41. Ellard SL, Clemons M, Gelmon KA, et al: Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCI Clinical Trials Group IND.163. J Clin Oncol 27:4536-4541, 2009.
42. Steelman LS, Navolanic P, Chappell WH, et al: Involvement of Akt and mTOR in chemotherapeutic-and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 10:3003-3015, 2011.
43. Gaur S, Chen L, Yang L, Wu X, Un F and Yen Y: Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors. Cancer Lett 311:20-28, 2011.
44. Moriceau G, Ory B, Mitrofan L, et al: Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res 70:10329-10339, 2010.
45. Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P and Holen I: Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 14:4658-4666, 2008.
46. Coleman RE, Winter MC, Cameron D, et al: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099-1105, 2010.